cbdMD annual operating margin
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
cbdMD's operating margin was −11.27% for fiscal 2025.
View full cbdMD company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-09-30 | −11.27% | +5.37 pp |
| 2024 | 2024-09-30 | −16.64% | +73.12 pp |
| 2023 | 2023-09-30 | −89.76% | +121.08 pp |
| 2022 | 2022-09-30 | −210.83% | −169.39 pp |
| 2021 | 2021-09-30 | −41.44% | +0.53 pp |
| 2020 | 2020-09-30 | −41.98% | +20.58 pp |
| 2019 | 2019-09-30 | −62.56% | +328.88 pp |
| 2018 | 2018-09-30 | −391.44% | −361.02 pp |
| 2017 | 2017-09-30 | −30.42% | +160.98 pp |
| 2016 | 2016-09-30 | −191.39% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q3 2026 | 2026-06-30 | −20.36% | −0.72 pp |
| Q2 2026 | 2026-03-31 | −14.20% | −3.97 pp |
| Q1 2026 | 2025-12-31 | −5.71% | −4.02 pp |
| Q4 2025 | 2025-09-30 | −14.53% | −7.58 pp |
| Q3 2025 | 2025-06-30 | −19.64% | −12.25 pp |
| Q2 2025 | 2025-03-31 | −10.23% | +21.97 pp |
| Q1 2025 | 2024-12-31 | −1.69% | +18.14 pp |
| Q4 2024 | 2024-09-30 | −6.95% | +256.98 pp |
| Q3 2024 | 2024-06-30 | −7.38% | +20.83 pp |
| Q2 2024 | 2024-03-31 | −32.20% | −10.93 pp |
| Q1 2024 | 2023-12-31 | −19.83% | +45.01 pp |
| Q4 2023 | 2023-09-30 | −263.92% | −86.56 pp |
| Q3 2023 | 2023-06-30 | −28.22% | +345.33 pp |
| Q2 2023 | 2023-03-31 | −21.27% | +29.09 pp |
| Q1 2023 | 2022-12-31 | −64.84% | +190.27 pp |
| Q4 2022 | 2022-09-30 | −177.36% | −118.20 pp |
| Q3 2022 | 2022-06-30 | −373.55% | −314.75 pp |
| Q2 2022 | 2022-03-31 | −50.36% | −15.04 pp |
| Q1 2022 | 2021-12-31 | −255.10% | −240.83 pp |
| Q4 2021 | 2021-09-30 | −59.17% | −20.44 pp |
| Q3 2021 | 2021-06-30 | −58.80% | −46.23 pp |
| Q2 2021 | 2021-03-31 | −35.32% | +24.26 pp |
| Q1 2021 | 2020-12-31 | −14.28% | +45.96 pp |
| Q4 2020 | 2020-09-30 | −38.73% | +15.87 pp |
| Q3 2020 | 2020-06-30 | −12.57% | +68.21 pp |
| Q2 2020 | 2020-03-31 | −59.59% | −23.62 pp |
| Q1 2020 | 2019-12-31 | −60.23% | +174.18 pp |
| Q4 2019 | 2019-09-30 | −54.60% | −74.21 pp |
| Q3 2019 | 2019-06-30 | −80.78% | −133.36 pp |
| Q2 2019 | 2019-03-31 | −35.97% | +152.73 pp |
| Q1 2019 | 2018-12-31 | −234.41% | −208.86 pp |
| Q3 2018 | 2018-06-30 | 19.61% | +29.60 pp |
| Q2 2018 | 2018-03-31 | 52.58% | +67.58 pp |
| Q1 2018 | 2017-12-31 | −188.70% | +159.33 pp |
| Q4 2017 | 2017-09-30 | −25.55% | — |
| Q3 2017 | 2017-06-30 | −9.99% | — |
| Q2 2017 | 2017-03-31 | −15.00% | — |
| Q1 2017 | 2016-12-31 | −348.03% | — |
Over the last five reported fiscal years, cbdMD's operating margin increased from −41.98% to −11.27%, a change of +30.71 percentage points. The latest reported quarter, Q3 2026, shows −20.36%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review cbdMD filings at SEC.gov ↗